Jonathan Naft’s Post

Did you know that 91 unique treatment regimens for #MultipleMyeloma were identified in the LocoMMotion trial? Check out our summary of the final analysis of LocoMMotion, presented at #EBMT24, to learn more! https://loom.ly/54m3V5g #mmsm #myeloma

Exciting data from Poseida announcing promising interim Phase 1 results for P-BCMA-ALLO1, an #allogeneic #CART therapy, in relapsed/refractory #multiplemyeloma. Data reveal a 91% overall response rate, including 100% ORR in BCMA-naïve patients, with no dose-limiting toxicities and favorable safety outcomes. These results from a heavily pretreated patient population were presented at the #IMS24 Annual Meeting, highlighting the potential of this #TSCM-rich off-the-shelf therapy. See press release at link below for additional information. #PoseidaProud #Immunotherapy #CellTherapy #CARTCellTherapy #CARTCell #GeneticEngineering

👃What’s the best way to approach device design for targeted intranasal delivery? According to Mark Allen, Andrew Fiorini, Shai Assia (Clexio Biosciences): “The best form of information gathering is to consult the patients themselves - they know their needs, and frustrations, better than anyone.” To find out how Cambridge Design Partnership helped Clexio Biosciences develop a bespoke device for their first-in-human trials, and other industry insights, get your copy of our e-book Breathing New Life: Industry Insights into the Future of Respiratory Drug Delivery. Click here to download 👉 https://lnkd.in/dYQPUaMx #intranasal #drugdelivery #devicedesign #medtech

#EHA2024 is almost upon us! To help navigate the exciting sessions, check out our top abstract list, as recommended by our expert steering committee, to see what’s hot in #lymphoma and CLL! View here https://loom.ly/ki6GllY #lymsm #lymphoma

Helping a client to get to their first-in-human studies with an innovative device design requires a deep understanding of user requirements and medical device development. Find out how Cambridge Design Partnership helped our client Clexio Biosciences to start their clinical trial. #Pharmaceutical #MedicalDevice #DrugDeliveryDevice

Updated efficacy and safety results from cohorts A and B from the CARTITUDE-2 trial were recently presented at #Tandem24. Read our summary of the key results to learn more: https://loom.ly/XyjPzoo #MMsm #MultipleMyeloma #myeloma

We are thrilled to introduce a groundbreaking feature for Testing Multiple Myeloma using our Mispa i3 analyzer! 📈🔬 Join us as Mr. Ag demonstrates the advanced capabilities of Mispa i3 in detecting Kappa & Lambda Light Chains, providing accurate and efficient diagnosis for Multiple Myeloma. This innovative technology is set to revolutionize the way we approach myeloma testing, ensuring better patient outcomes and enhanced diagnostic precision. Order Now : https://lnkd.in/gUxr7hYu Don't miss out on this informative session that showcases the future of diagnostic technology! 🚀 #Agappe #MispaI3 #MultipleMyeloma #KappaLambdaLightChains #DiagnosticInnovation #HealthcareTechnology #BetterDiagnostics #PatientCare 🔄 Share this post to spread the word and help us bring cutting-edge diagnostics to more healthcare professionals! 💡

Great example of how deep-learning technology can increase efficiency of case review processes by using automation. #ClinFlows DICOM workflow solutions, like #decidemedical, can serve as hub and connect to various cloud based imaging analysis tools as required per project. Looking forward to exploring this very interesting technology field!

🚀 Exciting news from AARDEX Group! We’ve teamed up with OnDosis to push the boundaries of what’s possible in clinical trials and precision medicine. 🌟 This partnership is all about revolutionizing #drug #dosing and making patient care more precise, effective, and safe. Why does this matter? Because optimizing how patients take their medications is at the heart of better health outcomes and clinical trials results. 💊💥 We’re expanding our #MEMS® ecosystem to bring the innovations that ensure patients get the right dose, every time. Here's to transforming clinical trials together and setting new standards for the future of clinical trials. 🙌 https://lnkd.in/e36ZyvKW #AARDEX #OnDosis #Partnership #ClinicalInnovation #PrecisionDosing #MEMS

Get excited! Check your inbox for our latest edition of Myopia Profile Digest, which has just landed. Powered by Vyluma, we are exploring the latest research on atropine, plus a Q&A on compounded vs commercially manufactured atropine, new science and more. Let's get started with The latest research on atropine: efficacy, ideal candidates and safety. The Childhood Atropine for Myopia Progression (CHAMP) trial is a randomized controlled trial that aimed to investigate the efficacy and safety profile of NVK002 0.01% and 0.02% atropine. This extensive trial gives us new insights on atropine as a myopia controlling agent, as well as new information on efficacy, ideal candidates and safety. https://lnkd.in/g_BCMDGk PS. Subscribe to Myopia Profile Digest and check all previous themed learning editions through the footer of any page on myopiaprofile.com! #myopia #myopiacontrol #myopiamanagement #professionallearning